New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 1, 2013
06:34 EDTCRISCuris shares should be bought on weakness, says Roth Capital
Roth Capital believes that the recent weakness in Curis was caused by statements from a physician who inaccurately described the resistance rates of Curis' Erivedge. The firm reiterates a $9 price target and Buy rating on the shares.
News For CRIS From The Last 14 Days
Check below for free stories on CRIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CRIS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use